Item 8.01 Other Events.

On October 13, 2021, NRX Pharmaceuticals, Inc. (the "Company") issued a letter to its shareholders that addresses the lawsuit recently filed by Relief Therapeutics Holding AG ("Relief") against the Company in New York State Court. The complaint alleges that the Company failed to honor its obligations under the Collaboration Agreement between Relief and the Company dated September 18, 2020 (the "Collaboration Agreement"). The letter advises shareholders of the Company's position with respect to many of the allegations in the complaint as well as reiterating the Company's continued intention to pursue the development and clinical approval of ZYESAMI™. A copy of the letter to shareholders is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits



Exhibit No.                                   Description
   99.1         Letter to Shareholders, dated October 13, 2021.

   104        Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses